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Analysis combining correlated 
glaucoma traits identifies five new 
risk loci for open-angle glaucoma
Puya Gharahkhani  1, Kathryn P. Burdon  2, Jessica N. Cooke Bailey  3, Alex W. Hewitt  2,  
Matthew H. Law  1, Louis R. Pasquale  4,5, Jae H. Kang  5, Jonathan L. Haines3, 
Emmanuelle Souzeau  6, Tiger Zhou6, Owen M. Siggs  6, John Landers6, Mona Awadalla6, 
Shiwani Sharma6, Richard A. Mills6, Bronwyn Ridge6, David Lynn7, Robert Casson8,  
Stuart L. Graham9, Ivan Goldberg10, Andrew White10,11, Paul R. Healey10,11, John Grigg10, 
Mitchell Lawlor10, Paul Mitchell11, Jonathan Ruddle12, Michael Coote12, Mark Walland12, 
Stephen Best13, Andrea Vincent13, Jesse Gale14, Graham RadfordSmith1,15, David C. 
Whiteman1, Grant W. Montgomery1,16, Nicholas G. Martin1, David A Mackey2,17,  
Janey L. Wiggs4, Stuart MacGregor1, Jamie E. Craig6 & The NEIGHBORHOOD consortium*
Open-angle glaucoma (OAG) is a major cause of blindness worldwide. To identify new risk loci for OAG, 
we performed a genome-wide association study in 3,071 OAG cases and 6,750 unscreened controls, 
and meta-analysed the results with GWAS data for intraocular pressure (IOP) and optic disc parameters 
(the overall meta-analysis sample size varying between 32,000 to 48,000 participants), which are 
glaucoma-related traits. We identified and independently validated four novel genome-wide significant 
associations within or near MYOF and CYP26A1, LINC02052 and CRYGS, LMX1B, and LMO7 using single 
variant tests, one additional locus (C9) using gene-based tests, and two genetic pathways - “response 
to fluid shear stress” and “abnormal retina morphology” - in pathway-based tests. Interestingly, some 
of the new risk loci contribute to risk of other genetically-correlated eye diseases including myopia and 
age-related macular degeneration. To our knowledge, this study is the first integrative study to combine 
genetic data from OAG and its correlated traits to identify new risk variants and genetic pathways, 
highlighting the future potential of combining genetic data from genetically-correlated eye traits for 
the purpose of gene discovery and mapping.
OAG is characterized by optic nerve damage and progressive loss of peripheral vision, with many patients remain-
ing undiagnosed until severe irreversible vision loss has occurred1,2. OAG has a significant genetic component 
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with a relative risk of over 9 in first-degree relatives of affected individuals compared to relatives of unaffected 
people3. Our previous genome-wide association studies (GWAS) have reproducibly identified several risk loci 
for OAG including TMCO1, CDKN2B-AS1, SIX6, CAV1, CAV2, ABCA1, AFAP1, GMDS, ARHGEF12, TXNRD2, 
ATXN2, and FOXC14–9. However, the majority of the genetic variance contributing to OAG remains unexplained, 
emphasizing that further studies to identify additional risk loci for OAG are required in order to make genetic 
risk prediction more clinically useful.
Optic disk parameters including cup area (CA; the central area), disc area (DA; the total area of optic disc 
including cup area and the surrounding area containing axons of the retinal ganglion cells), and vertical cup-disc 
ratio (VCDR; the ratio of the vertical diameter of cup area to the vertical diameter of the optic disc) are key 
measurements used to assess OAG diagnosis and progression10. Elevated intraocular pressure (IOP) is the major 
known risk factor for OAG2. We refer to CA, DA, VCDR, and IOP as OAG endophenotypes or quantitative traits. 
There are high genetic correlations between these quantitative traits and OAG, with several of the already known 
risk loci for these traits overlapping with each other and with OAG loci, demonstrating their utility as endo-
phenotypes11–14. These findings suggest that combining genetic data from OAG and its endophenotypes has the 
potential to increase the probability of identifying genetic variants that are common between traits, thus enabling 
the extraction of greater genetic power from valuable disease cohorts.
In this study, we sought to identify additional risk loci contributing to OAG susceptibility by (1) increasing 
the sample size for OAG, (2) combining GWAS data from OAG and its endophenotypes in order to increase our 
statistical power to identify new risk loci for OAG, and (3) applying gene and pathway based approaches.
Results
In total, 3,071 OAG cases from the Australian & New Zealand Registry of Advanced Glaucoma (ANZRAG) 
obtained in three phases of data collection, and 6,750 unscreened controls of European descent were used as 
the GWAS discovery dataset in this study (Supplementary Table 1). Five loci were associated with OAG at 
genome-wide significance level in the meta-analysis of GWAS results between the three phases of ANZRAG 
data (P < 5 × 10−8), including regions near or within CDKN2B-AS1, ABCA1, C14orf39 and SIX6, TMCO1, and 
ARHGEF12, all of which are now well established risk loci for OAG5–7,9. Manhattan and Q-Q plots are shown in 
Supplementary Figure 1. Genomic inflation factor lambda was 1.006 for this analysis.
Next, to increase the power of this study to identify new risk loci for OAG, we performed GWAS meta-analyses 
of ANZRAG OAG and each of the endophenotypes (CA, DA, VCDR, and IOP) that we obtained from our 
previous study11 (Supplementary Table 1). Before performing the meta-analyses, we confirmed validity of the 
endophenotypes for OAG by showing that there were significant genetic correlations between OAG and the endo-
phenotypes (ranging between 20% and 47%, Supplementary Table 2; p ≤ 0.018) using the cross-trait bivariate LD 
score regression approach15. By design, the endophenotype studies did not include any of the OAG cases. This was 
further confirmed in the LD score bivariate analyses where the intercepts were close to zero with 95% confidence 
intervals (CI) overlapping zero, indicating that there was not significant sample overlap between our OAG and 
the endophenotypes studies. Moreover, intercepts of the univariate LD score regression analyses16 were close to 
1 with 95% CIs overlapping 1 (Supplementary Table 3), indicating that there was no model misspecification and 
other sources of bias such as population stratification and cryptic relatedness in either study16.
Four genomic regions that were genome-wide significant in meta-analyses of ANZRAG OAG and one of the 
endophenotypes (Table 1), and were not previously known risk loci for OAG, and had at least P < 0.05 in the OAG 
separate analysis, were taken forward for validation. The best SNPs within these regions were rs72815193[G] 
Chr SNP Risk allele P-value Analysis
Meta-analysis 
heterogeneity P Nearest Genes
10 rs72815193 G 6.10 × 10−10 OAG + VCDR 0.31 MYOF and XRCC6P1
3 rs56962872 G 2.81 × 10−8 OAG + VCDR 0.51 LINC02052 and CRYGS
9 rs6478746 G 4.54 × 10−8 OAG + CA 0.44 LOC105376277 and LMX1B
1 rs148639588 T 3.53 × 10−8 OAG + CA 0.71 COL11A1
Table 1. Association results for the best SNPs within the genome-wide significant regions in meta-analyses of 
ANZRAG OAG and the endophenotypes. Effect sizes of these SNPs on OAG are presented in Table 2. OAG, 
open-angle glaucoma; CA, cup area; VCDR, vertical cup to disk ratio.
Chr SNP
Effect 
allele
Other 
allele
ANZRAG NEIGHBORHOOD combined
OR SE P-value OR SE P-value OR SE P-value
10 rs4918865^ C G 1.149 0.03 1.89 × 10−5 1.086 0.04 0.01958 1.119 0.02 2.31 × 10−6
3 rs56962872 A G 0.862 0.04 2.91 × 10−5 0.892 0.04 0.002324 0.876 0.03 3.03 × 10−7
9 rs6478746 A G 0.853 0.04 1.09 × 10−5 0.909 0.04 0.01231 0.879 0.03 9.10 × 10−7
13 rs9530458 T C 1.158 0.03 4.50 × 10−6 1.138 0.03 0.00018 1.148 0.02 3.45 × 10−9
Table 2. GWAS statistics for the new OAG loci in ANZRAG (the discovery OAG set), NEIGHBORHOOD (the 
replication OAG set), and combined (fixed-effect meta-analysis). ^rs4918865 in high LD with rs72815193, LD 
r2 = 0.93; OR, odds ratio; SE, standard error of regression coefficent.
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(risk alleles are indicated within brackets) (P = 6.10 × 10−10) on chromosome 10 near MYOF, XRCC6P1, and 
CYP26A1 for combined OAG and VCDR (in European and Asian ancestries), rs56962872[G] (P = 2.81 × 10−8) 
on chromosome 3 within LINC02052 and near CRYGS for combined OAG and VCDR (in European ancestry), 
rs6478746[G] (P = 4.54 × 10−8) on chromosome 9 near LOC105376277 and LMX1B for combined OAG and CA 
(in European ancestry), and rs148639588[T] (P = 3.53 × 10−8) on chromosome 1 near COL11A1 for combined 
OAG and CA (in European ancestry).
Of the above four loci that were genome-wide significant in our discovery meta-analyses, two loci 
(LOC105376277/LMX1B and LINC02052/CRYGS) were replicated (P < 0.0125, the Bonferroni-corrected thresh-
old considering four independent tests) for OAG in an independent replication study, the National Eye Institute 
Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD) 
(Supplementary Notes), containing 3,853 OAG cases and 33,480 controls8 (Table 2). Furthermore, rs72815193 
near MYOF and XRCC6P1 had a P = 0.06, and rs4918865 (in high LD with rs72815193; LD r2 = 0.93) 
Chr SNP
P-value OAG 
(ANZRAG)
P-value OAG 
(combined)* P-value CA P-value DA P-value VCDR P-value IOP Nearest gene
10 rs4918865^ 1.89 × 10−5 2.31 × 10−6 6.66 × 10−5 0.9062 2.10 × 10−5 0.3966 MYOF and XRCC6P1
3 rs56962872 2.91 × 10−5 3.03 × 10−7 0.000321 0.2832 0.000209 0.3793 LINC02052 and CRYGS
9 rs6478746 1.09 × 10−5 9.10 × 10−7 0.001659 0.6499 0.003575 0.03146 LOC105376277 and LMX1B
13 rs9530458 4.50 × 10−6 3.45 × 10−9 0.01305 0.2964 0.01631 0.04911 LMO7
Table 3. Association of the new loci with OAG and each of the endophenotypes separately. ^rs4918865 is in 
high LD with rs72815193, LD r2 = 0.93; *Meta-analysis of OAG in ANZRAG and NEIGHBORHOOD data; 
OAG, open-angle glaucoma; CA, cup area; DA, disk area; VCDR, vertical cup to disk ratio; IOP, intraocular 
pressure.
Figure 1. Regional plots for the new risk loci identified in single variant analyses in this study. The most 
significantly associated SNPs in each region are marked as solid purple diamonds. Pairwise correlations (LD 
r2) between the top SNP and the other SNPs in a 400 kb flanking region are illustrated by different colours. 
Blue spikes show estimated recombination rates. (a) rs72815193 on chromosome 10 near MYOF, CYP26A1, 
and CYP26C (the most significant results were obtained in combined OAG and VCDR analysis conducted in 
combined Asians and European ancestry). (b) rs56962872 on chromosome 3 within LOC253573 (LINC02052), 
near CRYGS and TBCCD1 (the most significant results were obtained in combined OAG and VCDR analysis 
conducted in European ancestry). (c) rs6478746 on chromosome nine near LMX1B (the most significant results 
were obtained in combined OAG and CA in European ancestry). (d) rs9530458 on chromosome 13 within 
LMO7 (combined OAG data from ANZRAG and NEIGHBORHOOD). cM = centimorgan.
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had a P = 0.02 for OAG in NEIGHBORHOOD. Although the SNPs near MYOF and XRCC6P1 did not 
pass the Bonferroni-corrected threshold of P < 0.0125, rs4918865 was more strongly associated with the 
high-tension glaucoma (HTG) subset (P = 0.003 for HTG vs. P = 0.37 for normal-tension glaucoma (NTG)) 
in NEIGHBORHOOD. The COL11A1 association was not replicated in NEIGHBORHOOD (P = 0.41 for 
rs148639588). The statistics including effect sizes of the top SNPs within the three new replicated loci with OAG 
separately (the meta-analysed OAG data from ANZRAG and NEIGHBORHOOD studies, without including the 
endophenotype data) are summarized in Table 2. All of the three new replicated loci were associated with CA and 
VCDR at, at least, nominal significance (P < 0.05), while LMX1B was also nominally (P = 0.03) associated with 
IOP (Table 3). Manhattan and Q-Q plots are shown in Supplementary Figure 1, and regional association plots in 
Fig. 1. Genomic inflation factor lambda ranged between 1.03 and 1.05 for these analyses.
Next, results for the SNPs that were not genome-wide significant, but approached this threshold (SNPs with 
P < 1 × 10−7) in the ANZRAG OAG meta-analysis or the meta-analysis of OAG and its endophenotypes, were 
combined with those from the NEIGHBORHOOD replication data, using a fixed-effects meta-analysis. A fourth 
locus on chromosome 13 within LMO7 that was nearly genome-wide significant in the OAG and CA (European 
ancestry) meta-analysis (rs9530458 [T], P = 2.71 × 10−7) became genome-wide significant (rs9530458 [T], 
OR = 1.148, P = 3.45 × 10−9) in the meta-analysis of the OAG data (ANZRAG discovery and NEIGHBORHOOD 
replication studies), without including the endophenotypes. This SNP was nominally associated with CA, VCDR 
and IOP (Table 3). Regional association for this locus is plotted in Fig. 1.
We also investigated association of the new loci with NTG and HTG subsets within the ANZRAG and 
NEIGHBORHOOD data (overall 1,546 NTG cases, 3,412 HTG cases, and 40,230 controls). The results summa-
rized in Supplementary Table 4 show that the 95% CIs overlap between the NTG and HTG analyses, suggesting 
that these loci may affect both NTG and HTG. However, larger sample sizes are required to further investigate 
this, as especially for NTG, the 95% CIs are quite wide, and for the LMO7 SNP (rs9530458) overlaps 1.
We performed a series of sensitivity analyses by excluding the ANZRAG cases in which visual field data 
was unavailable (585 people) as well as people with mixed-mechanism glaucoma (277 people with OAG as 
well as a secondary glaucoma) to ensure that the results were not driven by uncertainty in phenotype assign-
ment. The results from the sensitivity analyses in ANZRAG were meta-analysed with the endophenotype or 
NEIGHBORHOOD results as for the main analysis (Supplementary Tables 5 and 6). Overall, effect sizes obtained 
from the original and sensitivity analyses were similar, suggesting that our results were not biased by presence of 
any phenotype uncertainties.
Interestingly, rs72815193 and rs4918865 within the MYOF and XRCC6P1 locus are in high LD (r2 = 0.840 
and r2 = 0.9, respectively) with rs10882165, a SNP that has been shown to be associated with refractive error 
(P = 1 × 10−11)17, indicating that this locus may affect glaucoma and its endophenotypes as well as myopia. In 
addition, SNPs within LMO7 have been suggestively associated with corneal astigmatism (P = 4 × 10−6 for 
rs11841001)18. However, rs9530458 is in low LD (r2 = 0.14) with rs11841001 (P = 0.06 in the OAG and CA anal-
ysis in Europeans), suggesting that even if the LMO7 gene affects glaucoma as well as corneal astigmatism, this 
effect may come from independent risk variants within LMO7. On the other hand, the MYOF and XRCC6P1 
locus is ~1 Mb away from PLCE1, a known risk locus for VCDR. However, rs72815193 (MYOF) is not in LD with 
rs7072574 (PLCE1) (LD r2 = 0.001) (P = 3.86 × 10−6 in the OAG and VCDR analysis in Europeans), suggesting 
that these are independent loci.
Gene-based results. We used the approaches implemented in MetaXcan19, fastBAT20, and EUGENE21, to 
identify genes whose genetic variants or expression levels were significantly associated with development of OAG 
and its endophenotypes. These gene-based tests are complementary since they make different assumptions and 
use different approaches and input data to identify associated genes. After Bonferroni correction for multiple test-
ing (refer to the Methods section), nine genes (one from fastBAT, five from MetaXcan, and three from Eugene 
approaches, Table 4) that were genome-wide significant in the gene-based methods, and were not overlapping with 
Genes P-value Tissue Analysis Ndiscovery Approach
NEIGHBORHOOD 
replication P-value Nreplication
C9 4.93 × 10−7 NA OAG and IOP: European ancestry 187 fastBAT 0.04 87
FAM203A 2.70 × 10−8 Nerve_Tibial OAG and CA: European ancestry 5 MetaXcan 0.14 2
HERC4 1.06 × 10−9 Cells_Transformed_fibroblasts OAG and DA: European ancestry and Asians 1 MetaXcan 0.20 1
RNF26 2.6 × 106−9 Brain_Cerebellum OAG and IOP: European ancestry and Asians 5 MetaXcan 0.0004 5
NPAS4 3.97 × 10−9 Uterus OAG and VCDR: European ancestry and Asians 2 MetaXcan 0.05 2
CAPN1 1.02 × 10−8 Esophagus_Gastroesophageal_Junction OAG and VCDR: European ancestry 2 MetaXcan 0.12 2
DHRS7 1.00 × 10−6 brain OAG and CA: European ancestry and Asians 1 EUGENE 0.07 1
HLA-DQA2 1.00 × 10−6 brain OAG and DA: European ancestry 34 EUGENE 0.70 30
HLA-DQB1 1.00 × 10−6 brain OAG and DA: European ancestry 35 EUGENE 0.86 31
Table 4. Previously unreported genes that were genome-wide significant in gene-based approaches in the 
discovery datasets, with their corresponding results in the replication dataset (NEIGHBORHOOD). NA, Not 
Applicable (fastBat does use a tissue-specific approach); OAG, open-angle glaucoma; CA, Cup Area; DA, Disc 
Area; VCDR, Vertical Cup to Disc Ratio; IOP, Intraocular Pressure; Ndiscovery, Number of SNP(s) used in the 
discovery set; Nreplication, Number of SNP(s) used in the replication set.
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the known risk loci for OAG and its endophenotypes, were taken forward for validation in NEIGHBORHOOD. 
For MetaXcan and EUGENE approaches, we investigated replication of the significant genes in the same tissues 
that showed significance in the discovery set since the results from these approaches are tissue-specific.
One previously unreported gene became gene-wide significant (P < 7 × 10−7; see the Methods section) in the 
fastBAT approach (Table 4). This gene, complement factor 9 (C9) (P = 4.93 × 10−7 in the combined OAG and IOP 
analysis in European ancestry) was replicated in the NEIGHBORHOOD data (P = 0.04). The best result in the 
single variant tests for rs56345442, the top SNP within C9, was observed in the combined OAG and IOP anal-
ysis (P = 4.43 × 10−6 for combined European ancestry and Asians, and P = 9.998 × 10−6 in European ancestry), 
suggesting that a larger sample size would be required to detect this association at genome-wide significance 
threshold in the single variant analysis.
Five previously unreported genes were gene-wide significant (P < 5 × 10−8; see the Methods section) in the 
MetaXcan approach (Table 4), all of which were located within 1 Mb of a previously known locus. Of those genes, 
association of two genes, RNF26 (P = 2.66 × 10−9 in the discovery set) and NPAS4 (P = 3.97 × 10−9 in the dis-
covery set), were replicated in the NEIGHBORHOOD data (P = 0.0004 and P = 0.05 for RNF26 and NPAS4, 
respectively). However, four of the eQTL SNPs (rs1893261, rs11823300, rs61898351, and rs11217821) used by 
MetaXcan to impute the gene expression levels for RNF26 are in LD r2 = 0.3 with rs11827818, located within 
a previously known locus (near ARHGEF12) for IOP and OAG. Repeating the analysis without SNPs in LD 
r2 > 0.2 with rs11827818 (56 SNPs remained out of the original 60 SNPs) led to a non-significant result for this 
gene (P = 0.85). Similarly, excluding the eQTL SNPs in LD r2 > 0.2 with rs7931311, an already known locus 
near SCYL1 showed a non-significant association for NPAS4 (P = 0.82; twenty SNPs remained out of the original 
25 SNPs for this analysis). Although these results are valuable for the purpose of fine-mapping of the previously 
known associations, they suggest that RNF26 and NPAS4 are not new risk loci for OAG, but are driven by the 
eQTL SNPs within the previously known loci.
Three previously unreported genes were gene-wide significant (P < 9 × 10−6; see the Methods section) in brain 
using the EUGENE approach. However, none were replicated in brain using the EUGENE approach applied to the 
NEIGHBORHOOD data. Despite this, while DHRS7 was associated at P = 0.07 in brain in NEIGHBORHOOD, 
there was a stronger association at P = 0.0006 in blood. These data suggestively support that DHRS7 may also be 
a risk locus for OAG.
Accordingly, in addition to the risk loci identified in the single variant analyses, our gene-based approaches 
identified and validated C9 as an additional new risk locus for OAG. The previously reported OAG loci that 
also passed the gene-wide significance threshold in the gene-based tests included TMEM136 in the MetaXcan 
approach, AFAP1, AFAP1-AS, ARHGEF12, and TXNRD2 in the EUGENE approach, and TMCO1, ABCA1, 
C9orf53, CDKN2A, CDKN2B, CDKN2B-AS1, ARHGEF12, TMEM136, SIX1, SIX4, SIX6, AFAP1, GMDS, CAV1, 
and CAV2 in the fastBAT approach (Supplementary Table 7). These data provide further support for these genes 
being the target genes within the previously reported risk loci for OAG.
Pathway-based results. Two genetic pathways survived the significance threshold of P < 1 × 10−6 and false 
discovery rate < 0.05 in the pathway-based analysis in DEPICT22. One pathway was the “response to fluid shear 
stress” (GO: 0034405, P = 2.09 × 10−7, FDR < 0.01) in the combined OAG and CA analysis, and the other was 
“abnormal retina morphology” (MP: 0001325, P = 2.50 × 10−7, FDR < 0.01) in the combined OAG and VCDR 
analysis. The “abnormal retina morphology” pathway is interesting because it emphasizes that common risk loci 
between OAG and VCDR could be functioning through mechanisms related to retinal formation.
Gene expression. We also investigated the expression of the nearest genes to the best associated SNPs within 
the new OAG risk loci using RNA sequencing data from relevant human tissues including optic nerve, optic nerve 
head, retina, ciliary body pars plicata, trabecular meshwork, corneal endothelium, corneal stroma, and corneal 
epithelium (see Methods section). We observed a higher expression of LMX1B in trabecular meshwork, corneal 
endothelium, and corneal stroma, MYOF in trabecular meshwork and corneal epithelium, and LMO7 in corneal 
epithelium (Supplementary Figure 2). A relatively higher expression of LMX1B and MYOF in the trabecular 
meshwork is interesting because it is consistent with the previous observations for other known OAG genes such 
as MYOC showing high expression profile in the trabecular meshwork23. In addition, the LMX1B results are also 
consistent with the results from the GTEx eQTL studies where rs4837100, the SNP in high LD with the top vari-
ant in the LMX1B locus is an eQTL (P = 7 × 10−5) for LMX1B in sub-cutaneous adipose tissues24, suggesting that 
risk variants within this locus may alter expression levels of LMX1B.
Discussion
Our study identified four new OAG risk loci in single variant analyses as well as an additional locus using a 
gene-based approach. Interestingly, some of these new risk loci contribute to risk of other partially correlated eye 
diseases including age-related macular degeneration (AMD) and myopia (more details below). We also high-
lighted two genetic pathways associated with the development of OAG, one of which is gene-sets contributing to 
morphology of retina.
This study highlights the potential of combining genetic data from correlated eye traits for the purpose of gene 
discovery and mapping. We showed that meta-analysis of GWAS summary statistics from OAG and its correlated 
traits (VCDR, CA, DA, and IOP) is capable of identifying new risk loci by increasing statistical power. To our 
knowledge, this is the first study to use an integrative approach for OAG and its endophenotypes to identify new 
risk loci for OAG. This approach identifies risk variants common between OAG and its correlated traits, while 
increasing statistical power to detect variants with small effect sizes at the genome-wide significance threshold, 
which otherwise requires a much larger OAG sample for successful detection.
www.nature.com/scientificreports/
6SCIENTIFIC REPORTS |  (2018) 8:3124  | DOI:10.1038/s41598-018-20435-9
While all the new risk loci were at least nominally associated with CA and VCDR, none were associated with 
DA. This suggests that the new loci identified in this study are more likely to influence the size of the central area 
of the optic disk, rather than the total disc size. There have been some debates on whether the total size of the 
optic disc is a suitable trait to predict OAG risk and progression25. In this study we estimated a much smaller 
genetic correlation between DA and OAG as compared with genetic correlation between OAG and CA, VCDR, 
and IOP. In addition, the majority of the genome-wide significant loci in our meta-analyses of OAG and DA 
showed significant heterogeneity (P < 0.05) between the GWAS results from OAG and DA (data not shown), 
further suggesting that DA may not be as suitable as CA and VCDR to be used as an endophenotype for POAG.
Bioinformatics functional features of the newly identified risk loci or variants in high LD (r2 > 0.8) with them 
are discussed in Supplementary Materials. These loci are either quantitative trait loci that regulate the expression 
of genes within the regions, change sequence motifs for protein binding sites, or are located within DNAase 
hypersensitivity regions and within regions with enhancer or promoter motifs (Supplementary discussion).
rs72815193 is an intergenic SNP on chromosome 10 and is located near several genes including XRCC6P1, 
MYOF, CYP26A1, CYP26C1, and EXOC6. MYOF encodes a calcium/phospholipid-binding protein that plays a 
role in membrane repair of endothelial cells damaged by mechanical stress (http://www.genecards.org/cgi-bin/
carddisp.pl?gene=MYOF). CYP26A1 and CYP26C1 are involved in regulation of cellular retinoic acid metab-
olism, eye development, and maturation of vision function by their effect on retina and retinal ganglion cells 
during the later stages of eye development26–28. Interestingly, microdeletion of approximately 363 kb within this 
region of chromosome 10, which included CYP26A1, CYP26C1, and EXOC6, was reported in three patients 
affected by non-syndromic bilateral and unilateral optic nerve aplasia in a Belgian pedigree29. Moreover, this 
locus is also a risk locus for refractive error, where rs10882165 (P = 1 × 10−11 for refractive error) is in high LD 
with rs72815193 (r2 = 0.84), the top risk SNP within this locus17. XRCC6P1 is a pseudogene with limited data 
available on function of this gene or its relevance to diseases.
rs56962872 on chromosome 3 is an intronic variant within the LOC253573 (LINC02052) gene, near CRYGS 
and TBCCD1. LINC02052 is highly expressed in retina and vitreous humor CRYGS is a member of the crystallin 
gene families, which are expressed in human lens, retina, and cornea30. Mutations in CRYGS are associated with 
autosomal dominant paediatric cortical cataract in humans31. TBCCD1 is a centrosomal protein that plays a 
role in the regulation of centrosome and Golgi apparatus positioning, with consequences on cell shape and cell 
migration32. Interestingly, human XRP2 is a TBCC-domain containing protein mutated in certain forms of reti-
nitis pigmentosa, a retinal degenerative disease33,34. Thus, TBCC-domain containing proteins including TBCCD1 
may play a role in OAG through their effect on retinal formation or mechanisms such as cell shape and function.
rs6478746 on chromosome 9 is located near LMX1B and LOC105376277. LMX1B is mutated in Nail-Patella 
Syndrome, characterized by nail, patella and elbow dysplasia, in which some patients develop OAG35. In support 
of this, a mouse model study showed that a dominant-negative mutation of Lmx1b causes glaucoma36. This gene is 
required for murine trabecular meshwork formation and thus has an important role in controlling IOP37, suggest-
ing that this gene may influence OAG through the mechanisms related to increased eye pressure. In support of 
this, rs6478746 was nominally associated with IOP (P = 0.03), and associated at P = 6.38 × 10−7 in the combined 
OAG and IOP analysis in European ancestry.
rs9530458 is an intronic variant within LMO7, a protein-coding gene that may be involved in protein-protein 
interaction (http://www.genecards.org/cgi-bin/carddisp.pl?gene=LMO7&keywords=LMO7). An engineered 800 
kilobase deletion of Uchl3 and Lmo7 caused defects in viability, postnatal growth and degeneration of muscle 
and retina in mice38. In addition, LMO7 has been suggestively (P = 4 × 10−6 for rs11841001) associated with cor-
neal astigmatism. However, rs9530458 is not in high LD with the top corneal astigmatism SNP (rs11841001, LD 
r2 = 0.14, P = 0.06 in the OAG and CA analysis in Europeans), suggesting that independent variants within this 
gene may be involved in the development of OAG and corneal astigmatism.
C9, the gene identified in the gene-based approaches in this study also has interesting implications for OAG. 
This gene is one component of the complement system, a part of the innate immune response whose deregulation 
is considered to have a major role in pathogenesis of AMD39. Common and rare variants in multiple complement 
genes including C9 have been associated with AMD40–42, consistent with studies showing significant genetic correla-
tion between AMD and glaucoma43. Moreover, there is some evidence that the complement system including C9 is 
activated in glaucomatous optic nerve head astrocytes44, suggesting a possible role of C9 in the development of OAG.
This study has several limitations. First, we did not use the recently proposed approaches for meta-analysis of 
correlated traits using GWAS summary statistics45 which adjust for overlapping or related subjects, population 
stratification, and heterogeneity of effect between studies. In our study, as confirmed with the LD score regres-
sion analyses, we did not have biases such as population stratification and sample overlap between the OAG and 
endophenotype studies. Thus, we did not use the proposed approaches that adjust for such biases in this study. 
In addition, approaches such as that proposed by Zhu and colleagues are susceptible to detecting association for 
a trait that is mainly contributed to via only a subset of the traits. Although our approach has a similar limita-
tion, we investigated the heterogeneity of association between studies to ensure that the results were not biased 
towards one study. Another limitation of this study is that we performed the combined analysis of OAG and each 
endophenotype separately, rather than including all the endophenotypes in the same analysis. This was justified 
due to two reasons: (1) IOP and VCDR loci act through two distinct pathways (intraocular pressure vs optic disc 
morphology), and (2) the GWAS results for the endophenotypes included in this study were obtained from the 
same consortia study11, and thus the subjects overlap substantially between these phenotypes.
In conclusion, this study highlighted several novel genes and cellular pathways likely to be involved in the 
development of OAG. Fine-mapping and functional validation of the new risk loci will help to better understand 
disease pathophysiology. Identification of additional risk loci using larger sample sizes in the future may lead to 
more accurate genetic risk prediction algorithms for OAG as well as identification of new molecular targets for 
prevention and intervention strategies.
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Methods
Study design and participants. In total 3,071 OAG cases from the Australian & New Zealand Registry 
of Advanced Glaucoma (ANZRAG)46, and 6,750 unscreened controls of European descent were included in this 
study. This dataset involves three phases of OAG data collection, and hence, quality control (QC), imputation, and 
association analysis were conducted separately for each phase before combining the results in a meta-analysis. 
The first phase was previously published and comprises 1,155 advanced OAG cases and 1,992 controls geno-
typed on Illumina Omni1M or OmniExpress arrays (Illumina, San Diego, California, USA)7. The second phase 
includes a further 579 advanced OAG cases genotyped on Illumina HumanCoreExome array and 946 controls 
selected from parents of twins previously genotyped on the same array. The third phase comprises 1,337 OAG 
cases (11 advanced, 741 non-advanced, and 585 cases with visual field data unavailable) genotyped on Illumina 
HumanCoreExome array and 3,812 controls selected from a study of endometriosis previously genotyped on the 
same array. The diagnostic criteria have been described previously7. The Approval was obtained from the Human 
Research Ethics Committees of Southern Adelaide Health Service/Flinders University, University of Tasmania, 
QIMR Berghofer Medical Research Institute and the Royal Victorian Eye and Ear Hospital. Written informed 
consent was obtained from all participants. All the methods were carried out in accordance with relevant guide-
lines and regulations for human subject research, in accordance with the Declaration of Helsinki.
For the endophenotypes we used GWAS results from our previously published data, which includes vary-
ing numbers of participants for each trait; between 22,000 and 24,000 Europeans, and between 7,000 and 9,000 
Asians11 (Supplementary Table 1). By design, the endophenotype studies did not include any of the OAG cases. 
We combined the OAG GWAS results with the results obtained from the endophenotype GWASs in Europeans 
in the primary analysis as well as those obtained from combined European and Asian endophenotype GWASs in 
a secondary analysis. The QC, imputation, and association testing has been previously described for these stud-
ies11 as well as for the first phase of the ANZRAG OAG study7– specifically imputation was done using the 1000 
Genomes Phase 1 Europeans reference panel. The following paragraphs provide this information for the second 
and third phases of the ANZRAG OAG dataset.
Quality Control (QC). We used the same QC protocol as was used for the first phase of the ANZRAG OAG 
GWAS. Briefly, we performed QC using PLINK 1.947,48 by removing individuals with more than 3% missing 
genotypes, and SNPs with call rate less than 97%, minor allele frequency (MAF) < 0.01, and Hardy-Weinberg 
equilibrium P < 0.0001 in controls and P < 5 × 10−10 in cases. The same QC protocol was used for case and con-
trol datasets before merging to avoid mismatches between the merged datasets. We used PLINK1.9 to compute 
identity by descent based on autosomal markers, with one of each pair of individuals with relatedness of greater 
than 0.2 removed within each phase of the ANZRAG data as well as between the three phases. PLINK 1.9 was 
used to compute principal components for all participants and reference samples of known northern European 
ancestry (1000 Genomes British, CEU, Finland participants). Participants with PC1 or PC2 values > 6 standard 
deviations from the mean of known northern European ancestry group were excluded.
Imputation. Phasing of the genotyped SNPs was conducted using ShapeIT49 and imputation was performed 
using Minimac3 through the Michigan Imputation Server50, with the Haplotype Reference Consortium (HRC)51 
r1.1 as the reference panel. SNPs with imputation quality (r2) > 0.3 and MAF > 0.01 were carried forward for 
analysis.
Association testing. We assessed associations between SNPs and OAG status adjusted for sex and the first 
six principal components under an additive genetic model using the dosage scores obtained from imputation. 
Association analysis was performed either using SNPTEST v2.552,53 or PLINK 1.9. Genomic inflation factor 
lambda was calculated to investigate the presence of inflation due to model miss-specification or population 
stratification. We also performed a sensitivity analysis by excluding the OAG cases in which visual field data 
was unavailable to ensure that the association results were not driven by including those people in the analysis. 
Similarly, people with mixed-mechanism glaucoma (277 people with OAG as well as a secondary glaucoma) were 
excluded in a sensitivity analysis as a further robustness check. Association of the top loci were also investigated 
in NTG and HTG subsets within the ANZRAG dataset (821 NTG cases, 1,544 HTG cases, and 6,750 controls).
To increase the power of this study to identify new risk loci for OAG, we meta-analysed the OAG GWAS 
results with those obtained from the endophenotype GWASs. To confirm the validity of the endophenotypes for 
OAG, we estimated genetic correlation between OAG and the endophenotypes using the cross-trait bivariate LD 
score regression approach15. This approach estimates genetic correlation between traits from regression of the 
combined Z scores of each SNP for two traits obtained from GWAS summary statistics on LD scores calculated 
from a reference panel. LD scores are incorporated in estimation of genetic correlation based on the fact that 
SNPs with high LD have, on average, higher chi-square statistics for association with a trait as compared with 
SNPs with low LD. In addition, an intercept close to zero in these analyses indicates that there is not a significant 
sample overlap between studies. Moreover, we used the univariate LD score regression approach16 to investigate 
presence of model or structural bias in the OAG and endophenotype GWAS data. An intercept close to 1 in a 
univariate analysis indicates that there is no model misspecification and other sources of bias such as population 
stratification and cryptic relatedness16.
Meta-analysis of the ANZRAG OAG results between the three phases was performed in METAL54 using 
the fixed-effects inverse-variance weighting approach using SNP effect sizes and their standard errors. In addi-
tion, the quantitative trait GWAS results were meta-analysed with the ANZRAG OAG GWAS using the P-value 
approach in METAL. In this approach, Z scores are created for each SNP from P-values and direction of effect for 
tested alleles, and combined as weighted sum of the individual statistics where the weights are proportional to the 
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square root of the number of individuals examined in each study. Genomic control correction was applied to each 
GWAS dataset prior to the meta-analysis to ensure that inflation was not driving our results. We also investigated 
the heterogeneity of Z scores between studies using the approach implemented in METAL. Q-Q and Manhattan 
plots were created in R. For the purpose of creating these plots, we excluded genome-wide significant SNPs that 
showed heterogeneity of effect (Cochran’s Q Test P < 0.05) between OAG and the quantitative traits that included 
Asians. Regional association plots were created using LocusZoom55.
SNPs with P < 1 × 10−7 from the overall meta-analysed results that were previously unreported for OAG, 
and were at least nominally associated (P < 0.05) with OAG in the combined OAG and the quantitative trait 
analyses, were taken forward for validation in an independent US dataset, the National Eye Institute Glaucoma 
Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD), containing 
3,853 OAG cases and 33,480 controls8. More details on the NEIGHBORHOOD study has been provided in 
the Supplementary Notes.
Gene-based tests. Gene-based tests were conducted using the approaches implemented in MetaXcan19 
fastBAT20, and EUGENE21. We used the GWAS results from OAG as well as combined OAG and its endopheno-
types for the gene-based tests. MetaXcan is an extension of PredixCan56, a gene-based approach that uses GWAS 
summary results to impute the genetic component of gene expression in different tissues (thus eliminating the 
need to directly measure gene expression levels), and correlates the imputed gene expressions with phenotypes of 
interest. The Bonferroni-corrected threshold for multiple testing was set to 5 × 10−8, considering the maximum 
number of 7,230 genes tested in 44 tissues for three traits, OAG, IOP, and VCDR (note that VCDR is the ratio 
of CA to DA, so highly correlated with these traits). The MetaXcan method is developed based on the publically 
available European reference data; however, this method is quite robust to ethnicity differences19. Thus, we ran 
the MetaXcan analyses using European ancestry as well as combined Asians and European ancestry data. The 
combined ethnicity dataset was >80% European.
fastBAT (fast and flexible set-Based Association Test) is a gene-based approach that calculates the association 
p-values for a set of SNPs (within ±50 Kb of a gene for this study) using GWAS summary data while accounting 
for LD between SNPs. The Bonferroni-corrected significance threshold was set to 7 × 10−7, considering the max-
imum number of 24,654 genes tested for three traits. We ran the fastBAT analyses using European ancestry and 
Asians data separately, and combined P-values using the sum of Z scores method. In addition, we also used the 
combined Asians and European ancestry meta-analysis results as input for this analysis.
EUGENE is a gene-based approach that captures the aggregate effects of independent eQTL SNPs (both 
cis-acting and trans-acting) for each gene using GWAS summary statistics. The most suitable tissue for OAG that 
is available to use with the EUGENE approach is the brain tissue. Considering the maximum number of 5,487 
genes tested in brain for three traits, the Bonferroni-corrected threshold was set to 9 × 10−6. Since the current 
version of EUGENE is developed based on publically available European reference data, we ran the EUGENE 
analyses using the meta-analysis results from subjects with European ancestry only. However, since the combined 
ethnicity analyses comprised mainly (at least 80%) Europeans, we also ran these analyses using combined Asian 
and European ancestry data.
Pathway-based tests. We used the results from the ANZRAG OAG meta-analysis as well as the 
meta-analysis of ANZRAG OAG and its endophenotypes to do a pathway analysis using the approach imple-
mented in DEPICT22. Although it is preferable to use genome-wide significant loci for DEPICT provided there are 
at least 10 independent risk loci available for a trait, because we did not have this many independent genome-wide 
significant loci for each of the meta-analyses we used SNPs with P < 1 × 10−7 for the pathway analyses. Due to 
the polygenic nature of the studied traits, as well as our relatively low statistical power to detect SNPs with small 
effect sizes, including more associated SNPs in the analysis may result in improved power to detect associated 
pathways. Assuming that all the 14,463 pathways used by DEPICT are independent, and considering testing 
those pathways for three traits, we set the Bonferroni-corrected significance threshold to P < 1 × 10−6 and false 
discovery rate <0.05.
Gene expression. Ocular tissues of interest (corneal epithelium, corneal stroma, corneal endothelium, tra-
becular meshwork, pars plicata of the ciliary body, retina, optic nerve head and optic nerve) were collected from 
donor human eyes within 24 hours post-mortem (mean = 9.7 ± 5.3 hours) and fixed in RNAlater. RNA quality 
was assessed using Agilent Bioanalyzer 2100 RNA 6000 Nano Assay (Catalog #G2938C, Santa Clara, USA) (mean 
RNA integrity number = 6.5 ± 1.8) and concentrations were quantified on the Qubit® 2.0 Fluorometer (Catalog 
#Q32866, Carlsbad, USA) using Qubit™ RNA Assay Kits (Catalog #Q32852, Carlsbad, USA). 250 nanograms of 
total RNA from each tissue sample was indexed using Bioo Scientific® NEXTflex™ Rapid Directional mRNA-Seq 
Kit Bundle with RNA-Seq Barcodes and poly(A) beads (Catalog #5138-10, Austin, Texas) and sequenced on the 
Illumina NextSeq® 500 using High Output v2 Kit (75 cycles) (Catalog #FC-404-2005, San Diego, USA). All raw 
sequences were quality-control filtered and trimmed with Trimgalore v0.4.0 (http://www.bioinformatics.babra-
ham.ac.uk/projects/trim_galore/), aligned to the human genome (GRCh38 assembly) using TopHat v2.1.157,58 
and normalized using the trimmed mean of M-values (TMM) normalisation method59 in Bioconductor R pack-
age EdgeR v3.10.260. Gene differential expression was analysed using EdgeR software with Benjamini Hochberg 
false-positive adjustment61.
In silico functional analyses. Bioinformatics functional analyses were performed for the novel 
genome-wide significant loci using HaploReg62, RegulomeDB63, ENCODE Project Consortium64, and 
eQTL-browsers including Blood eQTL-Browser65 and GTEx-Browser24. The top SNP in each locus as well as 
those with LD r2 > 0.8 with the top SNPs were used for these analyses.
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Data availability. The datasets generated during and/or analysed during the current study are not publicly 
available due to ethical issues.
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